The 11 most recent market catalysts affecting $SLDB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 75
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Solid Biosciences reported its Q3 2026 financial results, highlighting a healthy cash position of $348.9 million, providing an operational runway into the first half of 2028. This …
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 65
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial
Solid Biosciences received Orphan designation from the European Commission for SGT-212, its gene therapy for Friedreich's ataxia. This designation provides incentives like market e…
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 75
Solid Biosciences shares are trading higher after the company announced multiple presentations at the ESGCT Annual Congress showcasing its SGT-003 gene therapy program and proprietary POLARIS-101 capsid platform.
This headline represents a significant corporate catalyst for Solid Biosciences. Positive presentations at a major scientific congress, especially concerning a gene therapy program…
Oct 15, 2026
Corporate Catalyst
Neutral
Impact 65
UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20
UBS analyst Joon Lee initiated coverage on Solid Biosciences (SLDB) with a 'Buy' rating and a $20 price target. This event is significant for SLDB as it represents a new institutio…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 65
RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18
RBC Capital's initiation of coverage on Solid Biosciences with an Outperform rating and an $18 price target is a significant event for the company. Analyst coverage, especially wit…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26
Cantor Fitzgerald analyst Kristen Kluska has maintained an 'Overweight' rating on Solid Biosciences (SLDB) and significantly raised the price target from $16 to $26. This action in…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20
Truist Securities analyst Danielle Brill maintained a 'Buy' rating on Solid Biosciences (SLDB) and raised the price target from $16 to $20. This analyst action signals increased co…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
Solid Biosciences Files Prospectus To Offer Up To $200M In Common Stock
Solid Biosciences filed a prospectus to offer up to $200 million in common stock. This action signals the company's intent to raise capital, likely to fund its ongoing research and…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
Solid Biosciences Files Prospectus For Mixed Shelf Offering; Size Not Disclosed
Solid Biosciences has filed a mixed shelf offering prospectus, which is a common corporate finance tool that allows a company to register various types of securities (e.g., common …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.